Qbrexza Availability Update: What Patients Need to Know in 2026

If you've been searching for updates on Qbrexza availability, you're in the right place. Qbrexza (glycopyrronium cloth, 2.4%) has been FDA-approved for primary axillary hyperhidrosis since June 2018, but patients in 2026 continue to report difficulty filling their prescriptions. This guide explains what's actually happening with Qbrexza supply, and what you need to know to get it filled.

Is Qbrexza on the FDA Shortage List in 2026?

As of 2026, Qbrexza is not listed on the FDA's official drug shortage database. The FDA tracks shortages when manufacturers cannot meet current or projected demand, and Qbrexza has not hit that threshold. Journey Medical Corporation continues to manufacture and supply the product.

However, the FDA shortage database only captures supply-side manufacturing issues. It does not reflect access problems caused by high prices, limited pharmacy stocking, insurance coverage gaps, or restricted dispensing networks — all of which affect Qbrexza patients in the real world.

Why Do Patients Still Struggle to Find Qbrexza?

The availability challenges patients face in 2026 come down to four main factors:

1. No generic version available. Qbrexza remains brand-name only. Without a generic competitor, there's no price competition driving broader pharmacy stocking.
2. High retail cost. At $840–$939 for a 30-day supply, Qbrexza has a high wholesale cost. Many pharmacies don't stock it if they don't see regular prescriptions for it in their area.
3. Insurance barriers. Many insurance plans require prior authorization for Qbrexza. Medicare does not typically cover it. When prescriptions can't be processed through insurance, patients often abandon the fill, reducing pharmacies' incentive to keep it on hand.
4. Preferred pharmacy network. The Journey Total Access Program routes commercially insured patients through a limited network of in-network pharmacies. Other pharmacies have less reason to stock the drug if the preferred channel isn't routing patients to them.

What Changed with Qbrexza Since Its Launch?

Qbrexza was originally developed by Dermira, Inc. and approved by the FDA in June 2018. The drug was later acquired by Journey Medical Corporation. In 2023, Journey Medical entered into a licensing agreement with Maruho Co. allowing Maruho to commercialize Qbrexza for hyperhidrosis treatment in South Korea, Taiwan, and Hong Kong — a sign that the drug is gaining international traction even as domestic access remains challenging for some U.S. patients.

Meanwhile, a competing topical anticholinergic — Sofdra (sofpironium gel, 12.45%) — entered the U.S. market, giving patients and prescribers another first-line topical option for axillary hyperhidrosis.

What the Qbrexza Savings Programs Look Like in 2026

Two programs from Journey Medical Corporation can help commercially insured U.S. patients access Qbrexza at significantly reduced cost:

• Journey Total Access Program: Commercially insured patients filling at an in-network pharmacy pay as little as $0 (if insured) or no more than $50 (if not covered). No savings card required at these pharmacies.
• Qbrexza Patient Savings Card: For commercially insured patients using an out-of-network pharmacy. Download from getqbrexza.com. Not valid for Medicare, Medicaid, or other government insurance programs.

For patients without commercial insurance or those on Medicare, discount coupons from GoodRx (as low as ~$630) and SingleCare (as low as ~$653) offer the next best savings option at participating pharmacies.

How to Navigate Qbrexza Availability in 2026

If your pharmacy says Qbrexza is unavailable, here's what to do:

• Use medfinder.com to have pharmacies near you called to check real-time stock
• Visit getqbrexza.com and use the pharmacy locator to find in-network Journey Total Access pharmacies
• Call Journey Medical patient support at 1-855-531-1859 for help enrolling in savings programs and finding stock
• Ask your pharmacy about special-ordering Qbrexza (typically a 1–3 day lead time)
• If all else fails, discuss alternatives to Qbrexza with your prescriber, including Sofdra or Botox injections

The Outlook for Qbrexza in 2026

While no generic version of Qbrexza is currently on the market, the availability of Sofdra as a competing topical anticholinergic may eventually push broader formulary coverage and competitive pricing improvements. For now, the best strategy is to know your options — from savings programs and in-network pharmacies to services that do the search work for you.